{"aliases":[{"type":"Synonym","name":"retifanlimab"},{"type":"USBrandName","name":"Zynyz"},{"type":"CodeName","name":"INCMGA-0012"},{"type":"CodeName","name":"INCMGA 0012"},{"type":"CodeName","name":"INCMGA00012"},{"type":"CodeName","name":"MGA 012"},{"type":"CodeName","name":"MGA012"},{"type":"CASRegistryName","name":"2226345-85-1"},{"type":"CodeName","name":"INCMGA0012"},{"type":"CodeName","name":"MGA-012"}],"definition":{"html":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab-dlwr binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.","text":"A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab-dlwr binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/retifanlimab-dlwr","text":"Retifanlimab-dlwr"},"nciConceptId":"C142168","nciConceptName":"Retifanlimab","termId":791453,"name":"retifanlimab-dlwr","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"retifanlimab"}